PBPaul Blomqvist

Paul Blomqvist

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul Blomqvist has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • A Ekbom

    Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden, bInstitute of Clinical Neuroscience, Department of Neurology, Gothenburg University, Sahlgrenska University Hospital, Gothenburg, Sweden, cPalliative Research Unit, Vrinnevi Hospital, Linköping University, Norrköping, Sweden, dThe Swedish Institute for Development of the Health Services, Stockholm, Sweden

    3 shared publications
  • A. Ekbom

    Department of Medical Epidemiology, Karolinska Institutet, Stockholm Sweden

    1 shared publication
  • Anders Ekbom

    Department of Medical Epidemiology, Karolinska Institutet, Box 281, SE-171 77 Stockholm, Sweden

    1 shared publication
  • Erik Nilsson

    Lund University

    1 shared publication
  • George Dafnis

    Eskilstuna Cty Hosp, Dept Surg & Urol, Colorectal Unit, SE-63188 Eskilstuna, Sweden

    1 shared publication
  • H Törnqvist

    1 shared publication

Latest Publications

  • A 10‐year survey of inflammatory bowel diseases—drug therapy, costs and adverse reactions

    by P. Blomqvist, N. Feltelius, R. Löfberg, A. Ekbom

    Background: Drug therapy for Crohn’s disease and ulcerative colitis is based on anti‐inflammatory and immunodulating drugs, nutritional support and surgical resection. Recently, new drugs have been introduced. Aim: To report drug prescriptions, costs and adverse reactions among inflammatory bowel disease patients in Sweden between 1988 and 1997. Methods: Drug use was calculated from the national Diagnosis and therapy survey and drug costs from prescriptions and drug sales. Adverse drug reactions were obtained from the Medical Products Agency’s National Pharmacovigilance system. Results: The annual drug exposure for Crohn’s disease was 0.55 million daily doses per million population, mainly supplementation and aminosalicylic acids. Mesalazine and olsalazine had 61% within this group. For ulcerative colitis patients, drug exposure was 0.61 million daily doses per million per year and aminosalicylic acids fell from 70% to 65%. For inflammatory bowel disease patients, corticosteroids and nutritional supplementation were common. The annual average cost for inflammatory bowel disease drugs was 7.0 million US dollars. Anually, 32 adverse drug reactions were reported, mainly haematological reactions such as agranulocytosis and pancytopenia (60%), followed by skin reactions. Only two deaths were reported. Aminosalicylic acids were the most commonly reported compounds. Conclusions: Drug use for inflammatory bowel disease in the pre‐biologic agent era rested on aminosalicylic acid drugs and corticosteroids with stable levels, proportions and costs. The level of adverse drug reactions was low but haematological reactions support the monitoring of inflammatory bowel disease patients.


  • Open Access

    Brain tumours in Sweden 1996: care and costs

    by P Blomqvist, J Lycke, P Strang, H Törnqvist, A Ekbom

    OBJECTIVES Brain tumours cause considerable concern due to a high mortality and there are increasing efforts to provide adequate care, sometimes outside hospitals. Health care utilisation, direct costs of care, and the indirect social cost of morbidity and early mortality caused by brain tumours in Sweden in the year 1996 was analysed. METHODS Quantification of ambulatory care, care in hospital, long term and palliative/terminal care, drug consumption, temporary as well as long term morbidity, and mortality from comprehensive national data sources. Direct costs were calculated using 1996 charges. Indirect costs were calculated by sex and age specific salaries. A sensitivity analysis considered the impact of alternative estimates of each item. RESULTS Indirect costs were 75% of the total and were caused mainly by early mortality. Direct costs were predominantly for care in hospital, long term care, and home health care. Among direct costs, astrocytomas III-IV and meningiomas accounted for 42% and 30% respectively. CONCLUSIONS The cost of illness from brain tumours reflects the characteristics of these malignancies. Despite their low incidence rate, the economic impact caused by high mortality among young persons is a predominant trait. Costs of acute hospital care and also long term care and home care are considerable.


  • Cholecystectomy in Sweden 1989 and 1994

    by Paul Blomqvist, Håkan Ljung, Erik Nilsson, Anders Ekbom


    • 1 July 2000
      • Vol. 35  (7)

    The introduction and development of colonoscopy within a defined population in Sweden.

    by G Dafnis, P Blomqvist, L Påhlman, A Ekbom


    • 1 May 2000
      • Vol. 27  (5) , 1171-7

    Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.

    by P Blomqvist, N Feltelius, A Ekbom, L Klareskog

    Many patients with rheumatoid arthritis (RA) need continuous medication, bringing considerable costs for drugs and a need for monitoring adverse drug reactions. We studied drug exposure, drug costs, and adverse drug reactions in patients with RA in Sweden from 1987 to 1997. Prescription patterns, drug costs, and adverse drug reactions, and their distributions and trends were analyzed by cross sectional annual data. Drug exposures and costs were assessed from the National Diagnosis and Therapy Survey. All costs were recalculated to the 1997 level using the drug price index. Information on adverse drug reactions was obtained from the national pharmacovigilance system. The drug prescription level was, on average, 2 defined daily doses (DDD) throughout the study period. Nonsteroidal antiinflammatory drugs (NSAID) accounted for > 40% of the drugs prescribed, methotrexate (MTX) 10%, corticosteroids 10%, and sulfasalazine 5%. Analgesics and opioids made up 14% of prescriptions - a low estimate considering the availability of over-the-counter preparations. Disease modifying antirheumatic drugs (DMARD) increased their proportion from 28.5 to 39.3%. Total costs were stable at $16 million US annually. NSAID costs decreased, while those of sulfasalazine, MTX, and cyclosporine increased. On average, 91 adverse drug reactions were reported annually. Hematological reactions (agranulocytosis, thrombocytopenia, leukopenia, pancytopenia) predominated, constituting 21% of reported reactions. Skin and gastrointestinal reactions, mainly mild, accounted for 15 and 14%, respectively. Deaths from adverse drug reactions were uncommon, about 3 per year, and were mainly attributed to hematological reactions. The total volume as well as the total cost of drug consumption for RA in Sweden was relatively constant during our 11 year observation period, despite a notable increase in the use of DMARD. This was mainly due to a decrease in costs per DDD of NSAID, and an increased use of cyclosporine. Drug related adverse reactions were dominated by hematological reactions, and fatal events were few. This emphasizes the need for an extended evaluation of which safety procedures are most cost effective for monitoring the drugs used for RA.